# psoriasis - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 38411
- Completion tokens: 48397
- Reasoning tokens: 6671
- Total tokens: 86808
- API requests reported: 4
- Elapsed seconds: 70.482
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The differential expression dataset comparing psoriatic lesional skin to normal control skin demonstrates a profound transcriptomic remodeling of the epidermal barrier, marked by massive upregulation of pro-inflammatory cytokines, antimicrobial peptides, cornified envelope structural proteins, and serine protease inhibitors, alongside specific downregulation of homeostatic epidermal growth factors and metabolic enzymes.

Out of 100 significantly altered molecular features ($FDR \le 0.01$), 90 are upregulated and 10 are downregulated. The dominant biological response reflects the canonical pathophysiological axis of psoriasis: an amplified IL-17 and IL-36 cytokine loop driving regenerative, hyperkeratotic epidermal hyperplasia. Elevated expression of alarmins (*S100A7*, *S100A7A*, *S100A8*, *S100A12*), beta-defensins (*DEFB4A*, *DEFB4B*, *DEFB103A*, *DEFB103B*), and inter-cellular cross-linking components (*SPRR2A-G*, *SPRR3*, *LCE3A*, *LCE3D*) underscores kerationcyte activation and altered differentiation. Concurrently, protease inhibitors (*SERPINB3*, *SERPINB4*, *PI3*) are highly induced to counteract epidermal proteolysis, while specific signaling ligands like *BTC* ($\text{log}_2\text{FC} = -4.30$) and long non-coding RNAs like *WAKMAR1* ($\text{log}_2\text{FC} = -5.63$) are markedly reduced, reflecting a loss of homeostatic epidermal differentiation.

---

### 2. Core Biological Programs

```
+---------------------------------------------------------------------------------------------------+
|                                  CORE BIOLOGICAL PROGRAMS                                         |
+------------------------------------+-----------------------+--------------------------------------+
| Program Name                       | Statistical Direction | Major Supporting Genes               |
+------------------------------------+-----------------------+--------------------------------------+
| 1. Epidermal Differentiation &     | Upregulated           | LCE3A, LCE3D, SPRR2A-G, SPRR3,       |
|    Cornified Envelope Assembly     |                       | KRT6A, PI3, GJB2, GJB6               |
| 2. IL-36 / IL-17 Pro-Inflammatory  | Upregulated           | IL36A, IL36G, IL36RN, IL19, IL20,    |
|    Antimicrobial Signaling         |                       | DEFB4A, DEFB4B, S100A7/A8/A12, GPR15LG|
| 3. Epithelial Protease-Inhibitor   | Upregulated           | SERPINB3, SERPINB4, SERPINB11/13,    |
|    & Antiprotease Balance          |                       | PI3, TMPRSS11D, KLK13, PRSS27        |
| 4. Lipid, Xenobiotic & Stress      | Mixed (Upregulated    | Upregulated: AKR1B10, PLA2G4D, KYNU, |
|    Metabolic Remodeling            | & Downregulated)      | VNN3P; Downregulated: CYP2W1, UGT3A2 |
| 5. Homeostatic EGF Ligand &        | Downregulated         | Downregulated: BTC, WAKMAR1,         |
|    Non-coding RNA Suppression      |                       | LOC107984452, LINC02660              |
+------------------------------------+-----------------------+--------------------------------------+
```

#### Program 1: Epidermal Differentiation & Cornified Envelope Assembly
* **Direction:** Upregulated
* **Major Supporting Genes:** *LCE3A* ($\text{log}_2\text{FC} = 8.30$), *LCE3D* ($\text{log}_2\text{FC} = 5.31$), *SPRR2A* ($\text{log}_2\text{FC} = 7.31$), *SPRR2B* ($\text{log}_2\text{FC} = 6.38$), *SPRR2D* ($\text{log}_2\text{FC} = 5.92$), *SPRR2E* ($\text{log}_2\text{FC} = 3.99$), *SPRR2F* ($\text{log}_2\text{FC} = 7.22$), *SPRR2G* ($\text{log}_2\text{FC} = 4.75$), *SPRR3* ($\text{log}_2\text{FC} = 7.18$), *KRT6A* ($\text{log}_2\text{FC} = 4.30$), *PI3* ($\text{log}_2\text{FC} = 9.24$), *GJB2* ($\text{log}_2\text{FC} = 4.42$), *GJB6* ($\text{log}_2\text{FC} = 3.02$).
* **Standardized Pathway:** Reactome: *Formation of the cornified envelope* (`R-HSA-6809371`); GO: *Epidermis Development* (`GO:0008544`).
* **Biological Explanation:** Keratinocytes under psoriatic stress undergo accelerated, aberrant differentiation (hyperkeratosis and parakeratosis). Small proline-rich proteins (SPRRs) and late cornified envelope proteins (LCEs) serve as substrate proteins cross-linked by transglutaminases, building a thickened skin barrier. Gap junction proteins (*GJB2*, *GJB6*) adapt inter-keratinocyte communication during hyperproliferation.
* **Evidence Strength & Limitations:** Strong in-sample co-expression and pathway enrichment across multiple independent structural gene families. However, transcript levels alone do not measure transglutaminase cross-linking efficiency or physical barrier integrity.

#### Program 2: IL-36 / IL-17 Pro-Inflammatory Antimicrobial Signaling
* **Direction:** Upregulated
* **Major Supporting Genes:** *IL36A* ($\text{log}_2\text{FC} = 11.37$), *IL36G* ($\text{log}_2\text{FC} = 5.68$), *IL36RN* ($\text{log}_2\text{FC} = 3.01$), *IL19* ($\text{log}_2\text{FC} = 7.58$), *IL20* ($\text{log}_2\text{FC} = 5.67$), *IL26* ($\text{log}_2\text{FC} = 4.36$), *DEFB4A* ($\text{log}_2\text{FC} = 11.18$), *DEFB4B* ($\text{log}_2\text{FC} = 11.03$), *DEFB103A* ($\text{log}_2\text{FC} = 5.76$), *DEFB103B* ($\text{log}_2\text{FC} = 5.75$), *S100A7* ($\text{log}_2\text{FC} = 7.09$), *S100A7A* ($\text{log}_2\text{FC} = 9.83$), *S100A8* ($\text{log}_2\text{FC} = 7.73$), *S100A12* ($\text{log}_2\text{FC} = 8.33$), *GPR15LG* ($\text{log}_2\text{FC} = 5.52$), *CXCL13* ($\text{log}_2\text{FC} = 5.89$), *CXCR2* ($\text{log}_2\text{FC} = 2.70$), *TNIP3* ($\text{log}_2\text{FC} = 7.28$), *ZC3H12A* ($\text{log}_2\text{FC} = 3.85$).
* **Standardized Pathway:** KEGG: *IL-17 signaling pathway*; Reactome: *Interleukin-36 pathway* (`R-HSA-9014826`); GO: *Antimicrobial Humoral Response* (`GO:0019730`).
* **Biological Explanation:** Synergistic activation of IL-17 and IL-36 cytokines induces keratinocytes to secrete antimicrobial peptides (defensins, S100 alarmins) and chemokines (*CXCL13*, *GPR15LG*), establishing a feedback loop that sustains leukocyte recruitment and tissue inflammation.
* **Evidence Strength & Limitations:** High expression changes across key drivers. A potential limitation is that immune cell infiltration (e.g., neutrophils, T-cells) in bulk tissue samples contributes to total RNA signals alongside intrinsic keratinocyte activation.

#### Program 3: Epithelial Protease-Inhibitor & Antiprotease Balance
* **Direction:** Upregulated
* **Major Supporting Genes:** *SERPINB3* ($\text{log}_2\text{FC} = 6.74$), *SERPINB4* ($\text{log}_2\text{FC} = 9.12$), *SERPINB11* ($\text{log}_2\text{FC} = 4.47$), *SERPINB13* ($\text{log}_2\text{FC} = 3.09$), *PI3* (Peptidase Inhibitor 3 / Elafin, $\text{log}_2\text{FC} = 9.24$), *TMPRSS11D* ($\text{log}_2\text{FC} = 7.75$), *KLK13* ($\text{log}_2\text{FC} = 4.05$), *PRSS27* ($\text{log}_2\text{FC} = 4.24$).
* **Standardized Pathway:** GO: *Endopeptidase inhibitor activity* (`GO:0004867`); Reactome: *Regulation of Proteolysis*.
* **Biological Explanation:** Skin inflammation triggers serine protease activity (e.g., *TMPRSS11D*, *KLK13*), which cleaves precursor cytokines like IL-36 into active forms. In response, keratinocytes produce ov-serpins (*SERPINB3/4*) and elafin (*PI3*) to regulate cellular processing, desquamation, and tissue remodeling.
* **Evidence Strength & Limitations:** Coordinated upregulation of both proteases and inhibitors indicates an active counter-regulatory mechanism. Protein-level activity and cleavage kinetics cannot be determined from RNA-seq abundance alone.

#### Program 4: Lipid, Xenobiotic & Stress Metabolic Remodeling
* **Direction:** Mixed (Upregulated & Downregulated)
* **Major Supporting Genes:** Upregulated: *AKR1B10* ($\text{log}_2\text{FC} = 6.27$), *AKR1B15* ($\text{log}_2\text{FC} = 5.23$), *PLA2G4D* ($\text{log}_2\text{FC} = 4.61$), *PLA2G4E* ($\text{log}_2\text{FC} = 2.47$), *KYNU* ($\text{log}_2\text{FC} = 4.42$), *FABP5* ($\text{log}_2\text{FC} = 3.65$), *VNN3P* ($\text{log}_2\text{FC} = 8.28$), *GDA* ($\text{log}_2\text{FC} = 5.90$). Downregulated: *CYP2W1* ($\text{log}_2\text{FC} = -4.70$), *UGT3A2* ($\text{log}_2\text{FC} = -4.59$).
* **Standardized Pathway:** KEGG: *Arachidonic acid metabolism*; GO: *Response to Lipopolysaccharide* (`GO:0032496`).
* **Biological Explanation:** Metabolic activity in psoriatic skin shifts toward lipid mediator synthesis (phospholipases *PLA2G4D/E*, fatty acid binder *FABP5*) and aldehyde detoxification (*AKR1B10/15*), alongside kynurenine pathway activation (*KYNU*). Concurrently, homeostatic detoxification enzymes (*CYP2W1*, *UGT3A2*) are suppressed.
* **Evidence Strength & Limitations:** Metabolic gene expression shifts are significant, but functional metabolic flux requires direct lipidomic and metabolomic validation.

#### Program 5: Homeostatic EGF Ligand & Non-coding RNA Suppression
* **Direction:** Downregulated
* **Major Supporting Genes:** *BTC* ($\text{log}_2\text{FC} = -4.30$), *WAKMAR1* ($\text{log}_2\text{FC} = -5.63$), *LOC107984452* ($\text{log}_2\text{FC} = -6.25$), *LOC105371988* ($\text{log}_2\text{FC} = -4.10$), *LINC02660* ($\text{log}_2\text{FC} = -3.90$).
* **Standardized Pathway:** GO: *Epidermal growth factor receptor signaling pathway*.
* **Biological Explanation:** Betacellulin (*BTC*), an EGFR ligand that maintains basal keratinocyte differentiation homeostasis, is markedly suppressed during active inflammation. Downregulation of homeostatic lncRNAs (e.g., *WAKMAR1*) reflects a broader reduction in normal epidermal regulatory networks in favor of inflammatory signaling.
* **Evidence Strength & Limitations:** Strong statistical confidence ($FDR < 10^{-60}$), but non-coding transcript functions in skin biology remain partially characterized.

---

### 3. Key Genes and Interaction Modules

```
+-----------------------------------------------------------------------------------------------------------------------+
|                                        KEY GENES AND INTERACTION MODULES                                             |
+--------------------------+-----------------------+-----------------------------+--------------------------------------+
| Gene / Module Candidate  | Statistical Signal    | Core Biological Program     | Proposed Relationship Type           |
+--------------------------+-----------------------+-----------------------------+--------------------------------------+
| 1. IL-36 Cascade Module  | IL36A (log2FC=11.37)  | Pro-inflammatory            | Pathway co-membership & Direct       |
|    (IL36A/IL36G/IL36RN)  | IL36G (log2FC=5.68)   | Signaling                   | Physical Interaction (Receptor)      |
|                          | IL36RN (log2FC=3.01)  |                             |                                      |
| 2. S100 Alarmin Cluster  | S100A7A (log2FC=9.83) | Antimicrobial Humoral       | Co-expression, Chromosomal           |
|    (S100A7/7A/8/12)      | S100A12 (log2FC=8.33) | Response                    | Cluster & Heterodimerization         |
|                          | S100A8 (log2FC=7.73)  |                             |                                      |
|                          | S100A7 (log2FC=7.10)  |                             |                                      |
| 3. Beta-Defensin Gene    | DEFB4A (log2FC=11.18) | Antimicrobial Response      | Co-expression & Gene Duplication     |
|    Duplication Cluster   | DEFB4B (log2FC=11.03) |                             | Copy-Number Variant                  |
| 4. Serpin Antiprotease   | SERPINB4 (log2FC=9.12)| Protease-Inhibitor Balance  | Co-expression & Functional           |
|    Module                | SERPINB3 (log2FC=6.74)|                             | Protease Antagonism                  |
| 5. Epidermal Envelope    | LCE3A (log2FC=8.30)   | Barrier Construction &      | Co-expression & Transglutaminase     |
|    Assembly Module       | SPRR2A (log2FC=7.31)  | Differentiation             | Substrate Cross-linking              |
|                          | SPRR3 (log2FC=7.18)   |                             |                                      |
| 6. IL-20 Family Axis     | IL19 (log2FC=7.58)    | Keratinocyte Hyperplasia    | Pathway co-membership & Paracrine    |
|    (IL19/IL20/IL26)      | IL20 (log2FC=5.67)    |                             | Receptor Activation                  |
| 7. Betacellulin (BTC)    | BTC (log2FC=-4.30)    | Homeostatic EGF             | Regulatory Antagonism to             |
|                          |                       | Suppression                 | Hyperproliferative Signals           |
| 8. Aldo-Keto Reductase   | AKR1B10 (log2FC=6.27) | Lipid & Stress Metabolism   | Pathway co-membership                |
|    Axis (AKR1B10/15)     | AKR1B15 (log2FC=5.23) |                             | (Aldehyde Detoxification)            |
| 9. Chemokine Leukocyte   | CXCL13 (log2FC=5.89)  | Inflammatory Infiltrate     | Receptor-Ligand Pathway              |
|    Recruitment Axis      | CXCR2 (log2FC=2.70)   | Homing                      | Co-membership                        |
+--------------------------+-----------------------+-----------------------------+--------------------------------------+
```

1. **IL-36 Cascade Module (*IL36A*, *IL36G*, *IL36RN*)**:
   * *Statistical Direction*: All upregulated (*IL36A*: $\text{log}_2\text{FC} = 11.37$; *IL36G*: $5.68$; *IL36RN*: $3.01$).
   * *Program Role*: Central driver of keratinocyte-mediated skin inflammation.
   * *Relationship Type*: Pathway co-membership and **direct physical interaction**. IL-36A and IL-36G bind the heterodimeric IL-1RL2/IL-1RAP receptor complex, while IL-36RN functions as a competitive physical inhibitor (supported by Reactome `R-HSA-9014826` and STRING physical binding records).
2. **S100 Alarmin Cluster (*S100A7*, *S100A7A*, *S100A8*, *S100A12*)**:
   * *Statistical Direction*: Upregulated (*S100A7A*: $\text{log}_2\text{FC} = 9.83$; *S100A12*: $8.33$; *S100A8*: $7.73$; *S100A7*: $7.10$).
   * *Program Role*: Chemotactic alarmins and antimicrobial peptides.
   * *Relationship Type*: Co-expression, chromosomal co-localization (Epidermal Differentiation Complex on 1q21), and **direct physical interaction** (S100A8 physically heterodimerizes with S100A9 to form calprotectin).
3. **Beta-Defensin Copy-Number Cluster (*DEFB4A*, *DEFB4B*, *DEFB103A*, *DEFB103B*)**:
   * *Statistical Direction*: Upregulated (*DEFB4A*: $\text{log}_2\text{FC} = 11.18$; *DEFB4B*: $11.03$).
   * *Program Role*: Direct broad-spectrum antimicrobial activity and chemokine-like immune cell attraction.
   * *Relationship Type*: Co-expression and gene duplication paralogs. *DEFB4A* and *DEFB4B* represent genomic copy-number variations encoding identical peptides.
4. **Serpin Antiprotease Module (*SERPINB3*, *SERPINB4*)**:
   * *Statistical Direction*: Upregulated (*SERPINB4*: $\text{log}_2\text{FC} = 9.12$; *SERPINB3*: $6.74$).
   * *Program Role*: Protection against excessive endogenous and exogenous proteolytic degradation.
   * *Relationship Type*: Co-expression, chromosomal tandem duplication (18q21), and **regulatory/functional enzyme antagonism** against cysteine/serine proteases.
5. **Epidermal Envelope Assembly Module (*LCE3A*, *SPRR2A*, *SPRR3*)**:
   * *Statistical Direction*: Upregulated (*LCE3A*: $\text{log}_2\text{FC} = 8.30$; *SPRR2A*: $7.31$; *SPRR3*: $7.18$).
   * *Program Role*: Structural reinforcement of parakeratotic stratum corneum.
   * *Relationship Type*: Co-expression and pathway co-membership as transglutaminase cross-linking substrates.
6. **IL-20 Family Axis (*IL19*, *IL20*, *IL26*)**:
   * *Statistical Direction*: Upregulated (*IL19*: $\text{log}_2\text{FC} = 7.58$; *IL20*: $5.67$; *IL26*: $4.36$).
   * *Program Role*: Paracrine induction of keratinocyte acanthosis and STAT3 phosphorylation.
   * *Relationship Type*: Pathway co-membership in IL-20 family receptor signaling.
7. **Betacellulin (*BTC*)**:
   * *Statistical Direction*: Downregulated ($\text{log}_2\text{FC} = -4.30$).
   * *Program Role*: Maintenance of non-inflammatory epidermal homeostasis.
   * *Relationship Type*: Regulatory antagonism; suppression of BTC accompanies the shift from homeostatic differentiation to regenerative inflammatory hyperplasia.
8. **Aldo-Keto Reductase Axis (*AKR1B10*, *AKR1B15*)**:
   * *Statistical Direction*: Upregulated (*AKR1B10*: $\text{log}_2\text{FC} = 6.27$; *AKR1B15*: $5.23$).
   * *Program Role*: Enzymatic detoxification of reactive aldehydes and lipid peroxidation products.
   * *Relationship Type*: Pathway co-membership and paralogous enzyme function.
9. **Chemokine Leukocyte Recruitment Axis (*CXCL13*, *CXCR2*, *GPR15LG*)**:
   * *Statistical Direction*: Upregulated (*CXCL13*: $\text{log}_2\text{FC} = 5.89$; *GPR15LG*: $5.52$; *CXCR2*: $2.70$).
   * *Program Role*: Chemotactic guidance of B-cells, T-cells, and neutrophils into lesional skin.
   * *Relationship Type*: Pathway co-membership and paracrine ligand-receptor interactions.

---

### 4. Validation Priorities

#### Priority 1: Functional Neutralization of the IL-36 Cytokine Axis
* **Classification:** Therapeutic target / Mechanistic hypothesis
* **Rationale:** *IL36A* ($\text{log}_2\text{FC} = 11.37$) and *IL36G* ($\text{log}_2\text{FC} = 5.68$) show large expression changes, while the endogenous antagonist *IL36RN* ($\text{log}_2\text{FC} = 3.01$) displays a smaller magnitude induction, suggesting an imbalance favoring pro-inflammatory signaling.
* **Current Dataset Evidence:** Concurrent high upregulation of IL-36 agonists and downstream targets (*DEFB4A*, *S100A7*).
* **External Evidence:** Monoclonal antibodies targeting IL-36R (e.g., spesolimab) demonstrate efficacy in generalized pustular psoriasis.
* **Next Steps:** Evaluate receptor binding occupancy and downstream NF-$\kappa$B activation in 3D organotypic psoriatic skin equivalents exposed to anti-IL-36R biologics.
* **Status:** Supported hypothesis

#### Priority 2: Serpin Protease Inhibitors as Markers of Disease Activity
* **Classification:** Biomarker
* **Rationale:** *SERPINB4* ($\text{log}_2\text{FC} = 9.12$) and *SERPINB3* ($\text{log}_2\text{FC} = 6.74$) are elevated in lesional tissue and secreted into circulation during active inflammation.
* **Current Dataset Evidence:** Strong upregulation across multiple serpin family members (*SERPINB3*, *SERPINB4*, *SERPINB11*, *SERPINB13*).
* **External Evidence:** Literature reports correlated serum SERPINB3/B4 levels with PASI (Psoriasis Area and Severity Index) scores (PMID: 40560938).
* **Next Steps:** Longitudinal validation of serum SERPINB3/B4 protein levels via ELISA in a prospective clinical cohort before and after anti-IL-17/IL-23 therapy.
* **Status:** Supported hypothesis

#### Priority 3: Betacellulin (*BTC*) Restoration & Homeostatic Re-differentiation
* **Classification:** Mechanistic hypothesis
* **Rationale:** *BTC* is down-regulated ($\text{log}_2\text{FC} = -4.30$), indicating loss of homeostatic EGFR activation.
* **Current Dataset Evidence:** Direct dataset signal showing strong, statistically significant reduction in *BTC* ($FDR = 1.78 \times 10^{-73}$).
* **External Evidence:** Reduced BTC expression is observed in hyperproliferative skin conditions; however, whether restoring BTC reverses hyperplasia or exacerbates EGFR-mediated growth remains unclear.
* **Next Steps:** Recombinant BTC treatment of primary human keratinocytes under inflammatory challenge (IL-17A + TNF-$\alpha$) to measure recovery of homeostatic differentiation markers.
* **Status:** Exploratory hypothesis

#### Priority 4: Aldo-Keto Reductase (*AKR1B10*) Inhibition in Epidermal Metabolism
* **Classification:** Therapeutic target / Mechanistic hypothesis
* **Rationale:** *AKR1B10* ($\text{log}_2\text{FC} = 6.27$) detoxifies retinals and lipid peroxides, supporting lipid metabolism in hyperplastic epithelium.
* **Current Dataset Evidence:** Co-induction of *AKR1B10* and *AKR1B15* ($FDR < 10^{-88}$).
* **External Evidence:** Small-molecule AKR1B10 inhibitors (e.g., epalrestat) modulate metabolic stress in tumor organoids (PMID: 39017606), but their utility in skin inflammation requires validation.
* **Next Steps:** Test specific AKR1B10 inhibitors in keratinocyte culture to examine impact on lipid mediator synthesis and cellular proliferation.
* **Status:** Exploratory hypothesis

#### Priority 5: Cell-Type Deconvolution of Bulk Tissue RNA Signals
* **Classification:** Confounding or composition check
* **Rationale:** Lesional skin biopsy samples contain hyperplastic keratinocytes alongside infiltrating immune cells (neutrophils, dendritic cells, T-cells).
* **Current Dataset Evidence:** Upregulation of myeloid/neutrophil markers (*S100A8*, *CXCR2*) alongside keratinocyte markers (*KRT6A*, *SPRR2A*).
* **External Evidence:** Single-cell RNA sequencing demonstrates that immune infiltration accounts for a portion of bulk cytokine and chemokine expression changes.
* **Next Steps:** Single-cell RNA sequencing or digital spatial transcriptomics on paired lesional and non-lesional skin biopsies to isolate cell-type-specific transcriptional shifts.
* **Status:** Supported hypothesis

---

### 5. Evidence Grounding

```
+------------------------------------------------------------------------------------------------------------------+
|                                           EVIDENCE GROUNDING MATRIX                                              |
+-----------------------------+---------------------+---------------------+--------------------+-------------------+
| Finding / Target            | Direct Input Data   | Pathway / Network   | Disease / Genetic  | Independent       |
|                             | (log2FC, FDR)       | Annotations         | Evidence           | Cohort Validation |
+-----------------------------+---------------------+---------------------+--------------------+-------------------+
| IL-36 Pathway Activation    | IL36A (+11.37)      | Reactome:           | GWAS / Monogenic   | Not performed     |
| (IL36A, IL36G, IL36RN)      | IL36G (+5.68)       | R-HSA-9014826       | DITRA syndrome     |                   |
| S100 Alarmin Secretion      | S100A7A (+9.83)     | GO:0019730          | Serum biomarker    | Not performed     |
| (S100A7, S100A8, S100A12)   | S100A12 (+8.33)     | STRING dimer        | correlation        |                   |
| Cornified Envelope Structural| LCE3A (+8.30)      | Reactome:           | LCE3B/3C deletion  | Not performed     |
| Genes (LCE3A, SPRR2A-G)     | SPRR2A (+7.31)      | R-HSA-6809371       | risk locus         |                   |
| Serpin Protease Inhibitors  | SERPINB4 (+9.12)    | GO:0004867          | Psoriasis lesion   | Not performed     |
| (SERPINB3, SERPINB4)        | SERPINB3 (+6.74)    | STRING network      | elevation          |                   |
| Betacellulin Suppression    | BTC (-4.30)         | GO: EGFR signaling  | Epidermal growth   | Not performed     |
| (BTC)                       | FDR=1.78e-73        | pathway             | alteration         |                   |
+-----------------------------+---------------------+---------------------+--------------------+-------------------+
```

#### Evidence Hierarchy & Integration
* **Direct Input Evidence:** The primary differential expression values ($\text{log}_2\text{FC}$, $P$-value, $FDR$) establish gene alterations in this study cohort.
* **Pathway & Network Evidence:** Reactome (`R-HSA-9014826`, `R-HSA-6809371`) and GO annotations (`GO:0019730`, `GO:0008544`) group individual genes into functional programs. STRING records confirm physical dimerizations (e.g., S100A8/A9 heterodimerization) and receptor-binding complexes (IL36A/IL1RAP). Databases such as QuickGO and Reactome rely on shared primary biochemical literature.
* **Disease & Genetic Context:** GWAS studies link the Epidermal Differentiation Complex (1q21) and *LCE3B/C* deletions to psoriasis susceptibility, aligning with observed structural gene inductions. Mutational loss of *IL36RN* causes Deficiency of IL-36 Receptor Antagonist (DITRA), supporting the pathogenic role of uninhibited IL-36 signaling.
* **External Statistical Validation:** **External statistical validation was not performed**, as no independent replication cohort or external dataset statistics were provided within the context. The interpretations above are derived from the present dataset alongside established biological annotations.

---

### 6. Limitations and Alternative Explanations

1. **Cell Composition Confounding (Keratinocyte vs. Immune Infiltration):**
   * *Issue:* Bulk tissue transcriptomics measures the average expression across all cell types present in skin biopsies. High upregulation of genes such as *S100A8* ($\text{log}_2\text{FC} = 7.73$) and *CXCR2* ($\text{log}_2\text{FC} = 2.70$) may reflect immune cell infiltration (neutrophils and T-cells) into lesional tissue, rather than increased expression per cell.
   * *Resolution:* Single-cell RNA sequencing (scRNA-seq) or spatial transcriptomics can isolate cell-type-specific signals.

2. **Epidermal Hyperplasia and Acanthosis (Structural Mass Shift):**
   * *Issue:* Psoriatic lesional skin exhibits epidermal thickening (acanthosis). An increased proportion of suprabasal keratinocytes relative to dermal fibroblasts in lesional biopsies can inflate the apparent expression of keratinocyte-specific genes (*SPRR2A*, *LCE3A*, *KRT6A*).
   * *Resolution:* Apply histological morphometry or cell-type deconvolution algorithms using baseline cell markers to adjust for structural cell proportion differences.

3. **Association vs. Causation Ambiguity:**
   * *Issue:* Transcriptional upregulation of protective antiproteases (*SERPINB3*, *SERPINB4*, *PI3*) and the antagonist *IL36RN* may represent secondary counter-regulatory feedback responses aimed at resolving inflammation, rather than primary drivers of disease initiation.
   * *Resolution:* Perform functional knockout or knock-down assays in organotypic human skin models to distinguish primary pathogenic drivers from protective feedback mechanisms.

4. **Absence of Independent Statistical Cohort Replication:**
   * *Issue:* While the internal statistical signals are strong ($FDR < 10^{-60}$ across top genes), no external independent cohort was evaluated in this dataset to test out-of-sample reproducibility.
   * *Resolution:* Validate candidate gene signatures in independent open-access psoriatic skin datasets (e.g., GEO/ArrayExpress cohorts) using pre-specified effect size thresholds.

5. **Lack of Proteomic and Post-Translational Correlation:**
   * *Issue:* Structural envelope assembly and cytokine activation depend heavily on post-translational modifications (e.g., transglutaminase cross-linking and proteolytic cleavage of precursor IL-36 isoforms). High transcript abundance does not guarantee active protein functional state.
   * *Resolution:* Perform Western blotting, enzyme-linked immunosorbent assays (ELISA), and active-site zymography on matched skin biopsy lysates.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=23, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
